Duration of Action of Verapamil SR
Verapamil sustained-release (SR) formulations have an elimination half-life of 12-17 hours and provide effective therapeutic coverage for 24 hours with once-daily dosing. 1
Pharmacokinetic Profile
The extended-release formulation of verapamil demonstrates significantly prolonged pharmacokinetics compared to immediate-release:
- Elimination half-life (ER): 12-17 hours 1
- Immediate-release half-life: 2-7 hours (single dose) or 4.5-12 hours (chronic dosing) 2
- Peak plasma concentration: Achieved at 5-7 hours after administration 2
Clinical Duration of Action
Sustained-release verapamil maintains blood pressure control throughout a 24-hour dosing interval when administered once daily. Multiple studies confirm:
- 24-hour efficacy: A single 240 mg SR dose maintains significant blood pressure reduction for up to 20 hours, with some attenuation in the final 4 hours of the dosing interval 3
- Consistent coverage: Both 24-hour ambulatory monitoring and clinical studies demonstrate maintained therapeutic effect throughout the day and night 4, 5
- Once-daily dosing: The SR formulation at 240-480 mg daily provides adequate rate control in atrial fibrillation and blood pressure control in hypertension 1, 6
Important Clinical Considerations
Hepatic Impairment
In severe liver dysfunction, the elimination half-life extends dramatically to 14-16 hours, requiring dose reduction to approximately 30% of normal dosing 2. This substantially prolongs the duration of action and increases risk of toxicity.
Overdose Context
Monitor patients for at least 48 hours after overdose with SR formulations due to delayed pharmacodynamic consequences 2. The sustained-release mechanism can result in prolonged drug absorption and extended toxic effects.
Food Effects
Food significantly reduces bioavailability of SR verapamil (AUC decreases by approximately 43%) but produces a narrower peak-to-trough ratio, which may actually enhance the sustained effect 2.
Dosing Implications
The 12-17 hour half-life supports: